

**Trends in the availability of the vulture-toxic drug,  
diclofenac, and other NSAIDs in South Asia, as revealed by  
covert pharmacy surveys.**

Journal:	<i>Bird Conservation International</i>
Manuscript ID	BCI-MP-2020-0003.R2
Manuscript Type:	Research Article
Date Submitted by the Author:	03-Jul-2020
Complete List of Authors:	Galligan, Toby; Royal Society for the Protection of Birds, Centre for Conservation Science Mallord, John; Royal Society for the Protection of Birds, Centre for Conservation Science Prakash, Vibhu; Bombay Natural History Society, Vulture Conservation Programme Bhusal, Krishna; Bird Conservation Nepal, Bird Conservation Nepal Alam, ABM ; IUCN, Bangladesh Country Office Ranade, Sachin; Bombay Natural History Society, Vulture Conservation Programme Prakash, Nikita; Bombay Natural History Society, Hornbill House, S.B. Singh Road Shringarpure, Rohan; Bombay Natural History Society, Hornbill House, S.B. Singh Road Kartik, Shastri; Bombay Natural History Society, Vulture Conservation Programme Dube, Alka; Bombay Natural History Society, Vulture Conservation Programme Dave, Ruchi; Bombay Natural History Society, Vulture Conservation programme Kumar, Yogesh; Bombay Natural History Society, Vulture Conservation Programme Anthony, Fergus; Bombay Natural History Society, Vulture Conservation Programme Chaudhary, Ishwari; Bird Conservation Nepal, na Chapagain, Devendra; Bird Conservation Nepal, Conservation Joshi, Ankit; Bird Conservation Nepal, Bird Conservation Nepal Paudel, Khadananda; Bird Conservation Nepal, na Kabir, Tarik; IUCN, Bangladesh Country Office Ahmed, Sakib; IUCN, Bangladesh Country Office Azmiri, Kazi; IUCN, Bangladesh Country Office Cuthbert, Richard; Royal Society for the Protection of Birds, RSPB Bowden, Christopher; RSPB, Conservation Green, Rhys; University of Cambridge, Zoology Department
Keywords:	Non-steroidal anti-inflammatory drugs, <i>Gyps</i> , India, Nepal, Bangladesh
Abstract:	The catastrophic declines of three species of Critically Endangered Gyps vultures in South Asia were caused by unintentional poisoning by the non-steroidal anti-inflammatory drug (NSAID) diclofenac. Despite a ban on its veterinary use in 2006 (India, Nepal, Pakistan) and 2010 (Bangladesh), residues of diclofenac have continued to be found in cattle carcasses and in dead wild vultures. Another NSAID, meloxicam, has been shown to be safe to vultures. From 2012 to 2018, we undertook

	<p>covert surveys of pharmacies in India, Nepal and Bangladesh to investigate the availability and prevalence of NSAIDs for the treatment of livestock. The purpose of the study was to establish whether diclofenac continued to be sold for veterinary use, whether the availability of meloxicam had increased and to determine what other veterinary NSAIDs were available. The availability of diclofenac declined in all three countries, virtually disappearing from pharmacies in Nepal and Bangladesh, highlighting the advances made in these two countries to reduce this threat to vultures. In India, diclofenac still accounted for 10-46% of all NSAIDs offered for sale for livestock treatment in 2017, suggesting weak enforcement of existing regulations and a continued high risk to vultures. Availability of meloxicam increased in all countries, and was the most common veterinary NSAID in Nepal (89.9% in 2017). Although the most widely available NSAID in India in 2017, meloxicam accounted for only 32% of products offered for sale. In Bangladesh, meloxicam was less commonly available than the vulture-toxic NSAID ketoprofen (28% and 66%, respectively, in 2018), despite the partial government ban on ketoprofen in 2016. Eleven different NSAIDs were recorded, several of which are known or suspected to be toxic to vultures. Conservation priorities should include awareness raising, stricter implementation of current bans, bans on other vulture-toxic veterinary NSAIDs, especially aceclofenac and nimesulide, and safety-testing of other NSAIDs on Gyps vultures to identify safe and toxic drugs.</p>

SCHOLARONE™  
Manuscripts

1 **Trends in the availability of the vulture-toxic drug, diclofenac, and other**  
2 **NSAIDs in South Asia, as revealed by covert pharmacy surveys.**

3 TOBY H. GALLIGAN,<sup>1†</sup>, JOHN W. MALLORD<sup>1\*</sup>, VIBHU M. PRAKASH<sup>2</sup>, KRISHNA P. BHUSAL<sup>3</sup>, A.B.M.  
4 SAROWAR ALAM<sup>4</sup>, FERGUS M. ANTHONY<sup>2</sup>, RUCHI DAVE<sup>2</sup>, ALKA DUBE<sup>2</sup>, SHASTRI KARTIK<sup>2</sup>, YOGESH  
5 KUMAR<sup>2</sup>, NIKITA PRAKASH<sup>2</sup>, SACHIN RANADE<sup>2</sup>, ROHAN SHRINGAPURE<sup>2</sup>, DEVENDRA CHAPAGAIN<sup>3</sup>,  
6 ISHWARY P. CHAUDHARY<sup>3</sup>, ANKIT B. JOSHI<sup>3</sup>, KHADANANDA PAUDEL<sup>3</sup>, TARIK KABIR<sup>4</sup>, SAKIB AHMED<sup>4</sup>,  
7 KAZI Z. AZMIRI<sup>4</sup>, RICHARD J. CUTHBERT<sup>1‡</sup>, CHRISTOPHER G.R. BOWDEN<sup>5</sup> and RHYS E. GREEN<sup>1,6</sup>

8 <sup>1</sup> RSPB Centre for Conservation Science, The Lodge, Sandy, Bedfordshire, SG19 2DL, UK

9 <sup>2</sup> Bombay Natural History Society, Hornbill House, Mumbai, 400023, India

10 <sup>3</sup> Bird Conservation Nepal, PO Box 12465, Lazimpat, Kathmandu, Nepal

11 <sup>4</sup> IUCN Bangladesh Country Office, House B-138, Lane 22, Mohakhali DOHS, Dhaka 1206, Bangladesh

12 <sup>5</sup> RSPB, Apartment 201, Sobha Jade, 2<sup>nd</sup> Floor, Block B, Jakkur, Yelahanka Hobli, Bangalore, North  
13 Taluk, Karnataka, 560 064, India

14 <sup>6</sup> Conservation Science Group, Department of Zoology, University of Cambridge, Downing Street, CB2  
15 3EJ, UK

16 \* Corresponding author: [john.mallord@rspb.org.uk](mailto:john.mallord@rspb.org.uk)

17 † Current address: 6 Itawara Place, Bridgewater, South Australia, Australia, 5155

18 ‡ Current address: World Land Trust, Blyth House, Bridge Street, Halesworth, Suffolk, IP19 8AB, UK

19

20 **Keywords:** Non-steroidal anti-inflammatory drugs, *Gyps*, India, Nepal, Bangladesh

21 **Running head:** Availability of NSAIDs in South Asia

22

23 **Summary**

24 The catastrophic declines of three species of Critically Endangered *Gyps* vultures in South Asia were  
25 caused by unintentional poisoning by the non-steroidal anti-inflammatory drug (NSAID) diclofenac.  
26 Despite a ban on its veterinary use in 2006 (India, Nepal, Pakistan) and 2010 (Bangladesh), residues  
27 of diclofenac have continued to be found in cattle carcasses and in dead wild vultures. Another  
28 NSAID, meloxicam, has been shown to be safe to vultures. From 2012 to 2018, we undertook covert  
29 surveys of pharmacies in India, Nepal and Bangladesh to investigate the availability and prevalence  
30 of NSAIDs for the treatment of livestock. The purpose of the study was to establish whether  
31 diclofenac continued to be sold for veterinary use, whether the availability of meloxicam had  
32 increased and to determine what other veterinary NSAIDs were available. The availability of  
33 diclofenac declined in all three countries, virtually disappearing from pharmacies in Nepal and  
34 Bangladesh, highlighting the advances made in these two countries to reduce this threat to vultures.  
35 In India, diclofenac still accounted for 10-46% of all NSAIDs offered for sale for livestock treatment in  
36 2017, suggesting weak enforcement of existing regulations and a continued high risk to vultures.  
37 Availability of meloxicam increased in all countries, and was the most common veterinary NSAID in  
38 Nepal (89.9% in 2017). Although the most widely available NSAID in India in 2017, meloxicam  
39 accounted for only 32% of products offered for sale. In Bangladesh, meloxicam was less commonly  
40 available than the vulture-toxic NSAID ketoprofen (28% and 66%, respectively, in 2018), despite the  
41 partial government ban on ketoprofen in 2016. Eleven different NSAIDs were recorded, several of  
42 which are known or suspected to be toxic to vultures. Conservation priorities should include  
43 awareness raising, stricter implementation of current bans, bans on other vulture-toxic veterinary  
44 NSAIDs, especially aceclofenac and nimesulide, and safety-testing of other NSAIDs on *Gyps* vultures  
45 to identify safe and toxic drugs.

46

2

47

48 **Introduction**

49 The non-steroidal anti-inflammatory drug (NSAID) diclofenac is nephrotoxic to *Gyps* vultures (Oaks *et al.* 2004, Swan *et al.* 2006a). The widespread use of diclofenac in South Asia during the 1990s and  
50 2000s to provide palliative care to dying cattle caused catastrophic declines in populations of the  
51 three resident *Gyps* vulture species endemic to the region, White-rumped *G. bengalensis*, Indian *G.*  
52 *indicus* and Slender-billed *G. tenuirostris* Vultures. Vultures were exposed to sufficient levels of  
53 contaminated food to cause the observed population declines when they fed upon carcasses of  
54 cattle which had been treated with diclofenac shortly before their death (Green *et al.* 2004, 2007).  
55 To save vultures from extinction, the Governments of India, Nepal and Pakistan banned the  
56 manufacture of veterinary formulations of diclofenac in 2006, followed by the Government of  
57 Bangladesh in 2010.

59

60 In India, repeated road transect surveys of vultures across much of their former range have shown at  
61 least a slowing of declines since the ban and a possible partial recovery in the population of White-  
62 rumped Vulture (Prakash *et al.* 2017). In addition, both the prevalence and concentration of  
63 diclofenac in cattle carcasses sampled throughout the same area declined between 2006 and 2009  
64 such that the estimated vulture death rate per meal decreased by about two-thirds (Cuthbert *et al.*  
65 2014). However, up to that time, the ban had not eliminated diclofenac from vulture food in India or  
66 allowed vulture populations to recover strongly. Furthermore, the proportion of vultures found dead  
67 in the wild in India with diclofenac residues showed only a slight and non-significant decline after the  
68 ban (Cuthbert *et al.* 2016).

69

70 Cuthbert *et al.* (2011) surveyed pharmacies selling veterinary drugs in India and found that many  
71 were stocking and selling human formulations of diclofenac for illegal use in cattle. This misuse was

3

72 made more practical by the manufacture and distribution to veterinary pharmacies, by some Indian  
73 pharmaceutical companies, of human formulations of diclofenac in large vials containing enough of  
74 the drug to dose cattle. This explained why many cattle carcasses were still found with diclofenac  
75 residues (Cuthbert *et al.* 2014), dead vultures were still found with diclofenac residues and visceral  
76 gout (Cuthbert *et al.* 2015), and vulture populations had not recovered strongly (Prakash *et al.*  
77 2017). The prevalence of diclofenac in cattle carcasses before and after bans in Bangladesh, Nepal  
78 and Pakistan was not measured. However, population surveys of vultures in Nepal and Pakistan have  
79 shown a reversal of declines since the bans on veterinary diclofenac (Chaudhry *et al.* 2012, Galligan  
80 *et al.* 2019).

81  
82 In 2015, the Government of India strengthened its regulations on diclofenac by banning the  
83 manufacture of human formulations in vials larger than a single human dose (3 ml). Two Indian  
84 pharmaceutical companies immediately challenged the ban, but it was upheld in the High Court of  
85 Madras in 2017. This strengthening of the ban may make diclofenac use in cattle less practical and  
86 expensive, because multiple small vials would need to be used, and further reduce the illegal use of  
87 human diclofenac formulations in cattle in India, though the legal challenge to the ban on the use of  
88 larger vials would have delayed this effect. Given the influence of India's pharmaceutical industry in  
89 the region and the far-ranging movements of vultures, this enhancement of the ban is expected to  
90 have a positive effect on vultures in neighbouring countries as well.

91  
92 Another NSAID, meloxicam, is the only veterinary NSAID known not to be toxic to *Gyps* vultures at  
93 doses likely to be used in veterinary practice (Swan *et al.* 2006b). Conservationists and governments  
94 in South Asia have been promoting the use of meloxicam while discouraging the use of diclofenac. In  
95 India, the prevalence of meloxicam in cattle carcasses increased by nearly half between 2006 and  
96 2009, whilst the prevalence of diclofenac decreased (Cuthbert *et al.* 2014a). In addition, the  
97 prevalence of diclofenac in cattle carcasses in India decreased most in regions where meloxicam

98 prevalence increased most (Cuthbert *et al.* 2014b). Counteracting this positive trend, there are many  
99 other NSAIDs available for use on cattle in South Asia, including aceclofenac, which metabolises into  
100 diclofenac in cattle (Galligan *et al.* 2016), ketoprofen and carprofen which are toxic to *Gyps* vultures  
101 (Naidoo *et al.* 2010, 2018), and nimesulide and flunixin, which have been found in dead wild *Gyps*  
102 vultures with visceral gout and are therefore probably vulture-toxic (Zorrilla *et al.* 2014, Cuthbert *et*  
103 *al.* 2015).

104

105 In this study, we undertook covert (undercover) surveys of pharmacies selling veterinary drugs in  
106 India, Nepal and Bangladesh to determine which NSAIDs are being sold for use in cattle. The use of  
107 covert surveys was necessary as the sale of diclofenac for veterinary purposes is illegal in all three  
108 countries and availability would otherwise have been significantly under-reported from overt  
109 surveys (Cuthbert *et al.* 2011). Our aims were to assess (1) how effective the ban on veterinary  
110 diclofenac has been, (2) whether the only known vulture-safe drug, meloxicam, has taken over from  
111 diclofenac as a preferred drug, and (3) what other NSAIDs are currently available.

112

### 113 **Methods**

114 Repeated covert surveys of pharmacies were carried out in eight regions of India, three regions of  
115 Nepal, and three regions in Bangladesh. Whereas the same regions were consistently surveyed in  
116 India and Nepal, the first survey in Bangladesh covered the whole country, while the second and  
117 third surveys were conducted in the country's two provisional Vulture Safe Zones (pVSZ) centred on  
118 the Sylhet and Khulna Divisions (administrative regions). The latter two surveys in Bangladesh,  
119 therefore, constituted repeat coverage of the same regions. The survey was based upon sampling of  
120 settlements, which were towns, villages or clusters of small villages. Settlements were selected at  
121 random within each region. Data were collected from just one pharmacy in each settlement visited,  
122 thus avoiding possible pseudoreplication arising from likely patterns among pharmacies within

123 settlements. The name, address and sometimes the geographical coordinates of each pharmacy was  
124 recorded by the survey team from the vehicle on the first survey and used to locate the same  
125 pharmacy in future years. In India and Bangladesh, surveyors were employees of the organisations  
126 undertaking the surveys (BNHS and IUCN Bangladesh, respectively), whereas in Nepal, a local man  
127 was paid to visit a pharmacy and purchase medicine for an injured cow.

128 Methods varied between countries. In India, a member of the survey team asked the pharmacist for  
129 “a painkiller for an injured cow”. However, in surveys in 2012 and 2013 in Jharkhand, Uttarakhand  
130 and Uttar Pradesh, surveyors specifically asked for, or a had a prescription, for diclofenac. Diclofenac  
131 was offered more frequently when the drug was specifically requested (44.2% of pharmacies),  
132 compared to when the standard method was followed (15.6%,  $\chi^2_1 = 42.38$ ,  $P < 0.0001$ ). Therefore,  
133 surveys that did not follow the standard method have been excluded from the modelling of trends  
134 over time. In Nepal, a prescription written by a veterinarian for one 30 ml vial of diclofenac and five  
135 tablets of deworming medication was presented to the pharmacist. In both India and Nepal, the first  
136 drug offered by the pharmacist was bought, regardless of what had been requested, although it was  
137 often the case that no drug was offered, because the pharmacist either did not stock, or had run out  
138 of, this type of drug. In Nepal, drugs intended for animals and humans are often sold in separate  
139 shops; therefore, surveys were conducted in both ‘Animal’ and ‘Human’ pharmacies, but it was  
140 always made clear that the drug purchased was intended for use on cattle. In Bangladesh, surveyors  
141 asked to see all NSAIDs in stock in each pharmacy. Data were collected from the packaging of the  
142 purchased (and in Bangladesh, stocked) drugs, including brand name, name and concentration of the  
143 active ingredient(s), vial size and the manufacturer’s name and address.

144

#### 145 *Statistical analysis*

146 Changes over time in the first NSAID offered for sale in India and Nepal were tested by fitting logistic  
147 regression models. Whether or not an NSAID was the first drug offered and subsequently bought



148 during a pharmacy visit was the binary dependent variable with binomial error and a log link  
149 function, and was modelled in relation to the calendar year as a continuous variable. The same  
150 modelling approach was used to study trends in the availability of individual NSAIDs, but only  
151 including data from pharmacy visits in which an NSAID of some kind was offered. Interaction terms  
152 between regions and year were not fitted and data for each region of India and Nepal were  
153 modelled separately. After inspecting the data, we included the quadratic effect of calendar year  
154 when modelling trends in sales of meloxicam in the Western Terai region of Nepal. We report the  
155 slope of the fitted logistic regression ( $b$ ) from these analyses and tested the statistical significance of  
156 its difference from zero using its asymptotic standard error and a  $t$ -test. This coefficient represents  
157 the modelled mean change per year in the logarithm of the odds of a drug being offered under a  
158 model in which the log odds is assumed to be a linear function of year. Negative  $b$  values indicate  
159 declines over time and positive values represent increases. Where data were only available from two  
160 surveys, i.e. the repeat survey of the two pVSZs in Bangladesh, we performed chi-square tests of  
161 association to investigate differences between surveys in the relative proportions of selected NSAIDs  
162 (proportion of all NSAIDs stocked that were meloxicam versus ketoprofen). The proportion of  
163 diclofenac offered in vials of different sizes before and after the ban on vials > 3 ml was also  
164 investigated with a chi-squared test of association.

#### 165 *Human ethics*

166 This study involved interactions with people, including staff of pharmacies and the local men  
167 recruited to collect data. The welfare of these participants was considered. Pharmacy staff were  
168 approached in their shops, open to the public, therefore, our interactions occurred in the public  
169 sphere, where a person accepts the responsibility of their actions and those actions can be publicly  
170 observed (Spicker 2011). Thus, pharmacy staff waive the rights normally given to participants in  
171 research (e.g. consent, withdraw, privacy; Spicker 2011), permitting covert interactions. Deceit to  
172 elicit a sale of diclofenac (i.e. asking for a painkiller for an animal and using a mock prescription) was

173 needed to uncover illegal behaviour. Covert interactions and deceit are important tools for data  
174 collection in conservation science, particularly when investigating illegal behaviour. Both are  
175 justified because obtaining accurate data would otherwise not be possible. Further, illegal  
176 behaviour is a concern of the public and public rights take priority over individual rights in such  
177 circumstances (Spicker 2011). In this case, the conservation of vultures and the ecosystem services  
178 that they provide are concerns of the public, and the sale of diclofenac and the killing of vultures in  
179 Bangladesh, India and Nepal are crimes and thereby concerns of the public.

180  
181 In India and Bangladesh, surveyors were members of conservation organisations managing the  
182 surveys and, therefore, understood the reasons behind the surveys. In Nepal, where local men were  
183 asked to collect data, they were given full information regarding the purpose of the survey. Thus,  
184 fully appraised, they were able to make an informed decision whether to participate or not, and  
185 were also given the right to withdraw at any time. No data were collected on the local men.

186  
187 Our study was sanctioned by state and national agencies responsible for wildlife protection and drug  
188 control through the respective countries' Government-endorsed Vulture Conservation Action Plans.  
189 A summary of our data was sent to the relevant authorities, although offending individuals were not  
190 reported, and are not identified in this paper.

191

192

## 193 **Results**

### 194 *India*

195 A total of 1452 covert pharmacy visits were made in all regions of India between 2012 and 2017,  
196 during which an NSAID was bought on 1129 (77.8%). No drug was offered on 15.0% of all visits (N =  
197 217). Of these cases, pharmacy staff refused to sell any drug on 35 of visits, most often (N = 25)  
198 because a prescription was not provided. An alternative drug, rather than an NSAID, was offered on

199 7.3% of visits (N = 106) and this was usually an antibiotic (N = 70). The proportion of pharmacies in  
200 which an NSAID was bought varied between regions (range, 54% (Central Gujarat) to 98% (Haryana  
201 pVSZ)) and declined significantly over the course of the study (effect of year,  $b = -0.392 \pm 0.05$ ,  $t =$   
202  $8.34$ ,  $P < 0.0001$ ). Of those pharmacies that did not offer any NSAID, 119 (37%) offered another type  
203 of drug. Where the data were recorded (n = 1108 visits), 78% of all NSAIDs were sold in injectable  
204 form, rather than a bolus, but the proportion of injectable forms was higher for diclofenac (97%).  
205  
206 Meloxicam, diclofenac, nimesulide and piroxicam accounted for the majority of NSAIDs sold (93%),  
207 the remainder consisting of six other drugs: aceclofenac, metamizole (tradename Analgin),  
208 ketoprofen, mefenamic acid, phenylbutazone and tolfenamic acid (Table 1). In those regions in  
209 which surveyors asked explicitly for diclofenac (Jharkhand, Uttarakhand and Uttar Pradesh), there  
210 was a significant reduction in the proportion of NSAIDs sold that were diclofenac between 2012  
211 (53.8%) and 2013 (14%,  $\chi^2_1 = 22.79$ ,  $P < 0.0001$ ). Excluding those region/year combinations in which  
212 the standard survey method was not used (see Methods), there were significant declines in the  
213 proportion of visits at which diclofenac was offered in both Assam and Madhya Pradesh, but there  
214 was a significant increase in southern Gujarat (Fig. 1a, Table 2). Diclofenac was bought in all five  
215 regions during the final survey in 2017 (10-46% of all NSAIDs sold). Across all surveys in India, only in  
216 Assam in 2016 was diclofenac not offered for sale, from a high of 30% of NSAIDs bought in 2012  
217 (Table 1). Diclofenac was either the most frequent or joint most frequently offered drug in both  
218 regions of Gujarat in 2017; and reached 20% of sales in Madhya Pradesh and Uttar Pradesh.  
219 Diclofenac was sold in various vial sizes (1, 2, 3, 9, 15, 30 and 50 ml) and manufactured in India (46  
220 companies overall, 15 companies in 2017). In 2012-2015, before the ban in 2016 on the production  
221 of large vials (> 3 ml) of diclofenac for human medicine, 92% (n = 224) of vials sold were > 3 ml, but  
222 this proportion significantly dropped to 54% (n = 76) after the ban (2016-2017;  $\chi^2_1 = 53.80$ ,  $P <$   
223  $0.0001$ ). Of those large vials sold after the government ban on large vials (n = 41), four (10%) had a  
224 manufacturing date that post-dated the ban, the rest consisted of older stock.

Commented [JM1]: TABLE 1; FIGURE 1A

225  
226 Meloxicam was the most commonly offered drug overall (36% of NSAIDs bought). There were  
227 significant increases in the proportion of visits where this drug was offered in Madhya Pradesh and  
228 Uttar Pradesh, but little evidence of change in Assam, Central Gujarat and Southern Gujarat (Table 2;  
229 Fig. 1b). In 2017, meloxicam constituted 15-46% of sales in the five regions surveyed using the  
230 standard method although it was more prevalent in other regions earlier in the study (Table 1). It  
231 accounted for the highest (or joint highest) sales in Southern Gujarat, Madhya Pradesh and Uttar  
232 Pradesh in 2017. There were near- significant increases in the proportion of visits where nimesulide  
233 was offered in Madhya Pradesh and Assam (Table 2; Fig. 1c). Nimesulide had the second-highest  
234 sales in the Haryana pVSZ (37%) in 2017. Including only those regions where the drug was prevalent  
235 (Madhya Pradesh and Uttar Pradesh), sales of piroxicam remained stable (Table 2). In 2017,  
236 piroxicam was the most frequently bought drug in Madhya Pradesh (30%), and the second most  
237 frequently bought drug in Uttar Pradesh (25%).

Commented [JM2]: TABLE 2; FIGURE 1B; FIGURE 1C

238  
239 *Nepal*  
240 A total of 774 covert visits to 'Animal' pharmacies were made between 2012 and 2017, during which  
241 an NSAID was bought at 594 (76.7%), the proportion declining over the course of the study (year,  $b =$   
242  $-0.211 \pm 0.04$ ,  $t = 5.00$ ,  $P < 0.0001$ ). In all cases where an 'Animal' pharmacy did not sell an NSAID, no  
243 other drug was offered. Where the data were recorded ( $n = 593$ ), 95% of NSAIDs were sold in  
244 injectable form, rather than a bolus.

245  
246 Meloxicam was by far the most prevalent NSAID bought in 'Animal' pharmacies (92.9% of NSAIDs,  $n$   
247  $= 594$ ), with five other drugs being sold in a few pharmacies (Table 3). The trend in the proportion of  
248 meloxicam bought varied between regions (Table 3). In the Western Terai, after an initial increase,  
249 there was evidence of a decline in the final survey in 2016 (Table 4; Fig. 2a). Sales of diclofenac,  
250 relative to all NSAIDs, were low in all surveys ( $n = 8/594$ , 1.3%), and the drug completely disappeared

251 from pharmacies in two regions (Fig. 2b). On all eight occasions when diclofenac was bought, it was  
252 of human formulations in large (30 ml) vials, and occurred both before and after the ban by the  
253 Government of India on the production of large vials. Those bought in the latest surveys (2017; n =  
254 2) were manufactured in March 2015. Nimesulide was bought with increasing frequency across the  
255 course of the study (Table 4), with a particularly sharp rise in the Western Terai ( $b = 1.437 \pm 0.54$ ,  $t =$   
256  $2.65$ ,  $P = 0.008$ ; Fig. 2c).

Commented [JM3]: TABLE 3; TABLE 4; FIGURE 2A;  
FIGURE 2B; FIGURE 2C

257  
258 A total of 672 covert visits were made to 'Human' pharmacies, during which an NSAID was bought  
259 for use on cattle on only 30 (4.5%) occasions. The drug bought was almost always diclofenac and was  
260 sold in 3 ml (n = 25) and 30 ml vials (n = 5). Sales of diclofenac in 'Human' pharmacies significantly  
261 declined from 18/80 (22.5%) in 2013 to 1/184 (0.5%) in 2017 ( $\chi^2_1 = 37.03$ ,  $P < 0.0001$ ). The non-  
262 NSAID paracetamol (acetaminophen) was also offered during two visits.

#### 264 *Bangladesh*

265 Covert visits were made to a total of 215 pharmacies in the first survey, in 102 (47%) of which  
266 NSAIDs were available to buy for veterinary use. In the second and third surveys, 128 (Sylhet, n = 66;  
267 Khulna, n = 62) and 129 (Sylhet, n = 71; Khulna, n = 58) pharmacies were visited, in which NSAIDs  
268 were available in 97%. The absolute number of NSAID products stocked by pharmacies was 1095  
269 (first survey = 340, second survey = 374 and third survey = 381; Table 5). In those pharmacies  
270 stocking NSAIDs, the maximum number of different drugs was six, although most carried just one or  
271 two. Where the data were recorded (n = 1091), 84% of NSAIDs were available in injectable, rather  
272 than bolus, form (82-100% in different regions).

273  
274 Combining all regions and surveys, of the 1,095 NSAID products stocked, the majority were either  
275 ketoprofen or meloxicam (94%; Table 5). Across the two repeat surveys in the Sylhet and Khulna  
276 pVSZs, there was a significant decline in the proportion of ketoprofen available (Fig. 3a) relative to

277 meloxicam (Fig. 3b;  $\chi^2_1 = 4.88$ ,  $P = 0.027$ ). The availability of other NSAIDs was low in all surveys,  
278 including diclofenac, stocks of which declined to zero in the final survey (Table 5; Fig.3c).

279

280 Diclofenac was available in only two large vial sizes (30 and 50 ml) and was manufactured by  
281 companies in Bangladesh and India. Where it was recorded ( $n = 1078$ ), 59% of all NSAIDs were  
282 manufactured by a single company and 89% by just six companies.

283

## 284 Discussion

285

### 286 *The effect of differences in survey methods*

287 Different methods were used in each of the countries surveyed. In India surveyors asked for a  
288 painkiller for their injured cow, in Nepal a prescription for diclofenac was presented to the  
289 pharmacist and in Bangladesh surveyors asked to see all NSAIDs stocked. These differences make  
290 comparisons between countries of the *absolute* levels of availability of drugs invalid. Asking for a  
291 specific drug is likely to increase the frequency with which that drug is offered by a pharmacist.  
292 However, the same method was used for surveys *within* each region and country, so we maintain  
293 that comparisons within regions and countries of trends over time are valid. Notwithstanding the  
294 above, in those countries (Nepal and Bangladesh) where diclofenac was specifically asked for, by the  
295 end of the survey period availability of this drug was very low. This suggests that we are justified in  
296 concluding that conservation organisations and government authorities in Nepal and Bangladesh  
297 have had greater success in removing veterinary diclofenac from pharmacies than they have in India.

298

299 Sales of the vulture-toxic NSAID diclofenac declined across all three countries surveyed, but the  
300 extent varied markedly, the drug all but disappearing from Nepal and Bangladesh, but remaining  
301 common in most regions of India. In contrast, the availability of the vulture-safe drug meloxicam  
302 increased, or remained high, across many regions, especially in Nepal. However, other NSAIDs, some

Commented [JM4]: TABLE 5; FIGURE 3A; FIGURE 3B;  
FIGURE 3C

303 of them known or suspected to be toxic to vultures, remained prevalent, especially ketoprofen in  
304 Bangladesh.

305

306 *The decline in diclofenac*

307

308 Although the governments of India, Nepal and Pakistan banned the veterinary use of diclofenac in  
309 2006 and Bangladesh did so in 2010, our data reveal that the ban did not eliminate sales of the drug  
310 in India. By the start of our surveys (2012), six years after the ban, diclofenac still accounted for the  
311 largest share (44%) of NSAIDs offered for sale in India. However, our data suggest that the  
312 strengthening of the ban to include all large (> 30 ml) vials of diclofenac may have been partially  
313 successful in reducing its prevalence in favour of other drugs. Over half the diclofenac bought after  
314 the strengthening of the ban was in large vials, and most of these consisted of old stock,  
315 manufactured before the ban. Notably, the large vials manufactured after 2015 were all illegally  
316 manufactured by Indian pharmaceutical companies.

317

318 The proportion of diclofenac sold in India declined over the period covered by our surveys. This may  
319 be attributable to awareness-raising programmes that occurred alongside our surveys, which  
320 included meetings with veterinarians, pharmacists, livestock owners and veterinary and pharmacy  
321 associations. Variation in the implementation of such advocacy may be part of the reason for the  
322 variation in trends in diclofenac sales between regions. For instance, in Assam, diclofenac sales  
323 dropped to zero after five annual surveys; whereas, in Gujarat (Central and Southern), after a decline  
324 between 2012 and 2013, sales increased again by the time of the next survey and awareness-raising  
325 programme in 2017. Thus, awareness-raising needs to be continued if it is to be effective.

326

327 The slow and incomplete reduction in diclofenac availability in veterinary pharmacies is the probable  
328 cause of the decline in the prevalence and concentration of diclofenac in cattle carcasses since 2006

329 (Cuthbert *et al.* 2014a). These changes may be starting to have an impact on vulture populations,  
330 with the declines in White-rumped *Gyps bengalensis*, Indian *G. indicus* and Slender-billed Vultures *G.*  
331 *tenuirostris* in India having slowed since the ban on diclofenac (Prakash *et al.* 2017).

332  
333 In contrast to the situation in India, diclofenac virtually disappeared from pharmacies in both Nepal  
334 and Bangladesh. This may have been due to effective advocacy and education, as well as strong  
335 government support, especially in promoting meloxicam in Nepal. However, the fact that most  
336 diclofenac is manufactured by Indian companies may contribute significantly. The one Nepali  
337 company found to be manufacturing 30 ml vials of diclofenac for human use during the first 'Human'  
338 pharmacy survey, voluntarily stopped after being asked to do so by conservationists. Diclofenac  
339 could still find its way into cattle via importation across the long, permeable borders with India,  
340 where it is more easily obtainable (K. Paudel, unpublished information), although the rapid partial  
341 recovery of White-rumped Vulture populations in Nepal since 2013 (Galligan *et al.* 2019) suggests  
342 that this is not happening on a large scale. Meanwhile, the recent strengthening of the ban in India  
343 will also reduce the risk of diclofenac imports and benefit vultures in Nepal and Bangladesh.

344  
345 *The rise of meloxicam*

346  
347 Sales of meloxicam increased in some of the regions we surveyed, and was the most common drug  
348 sold in pharmacies in Nepal. In India and Bangladesh, although availability increased in some regions,  
349 meloxicam was rarely the most common NSAID sold. Meloxicam is the only NSAID that has been  
350 shown through safety testing (Swan *et al.* 2006b; Swarup *et al.* 2007) to be non-toxic to *Gyps*  
351 vultures at doses they are likely to be exposed to in the wild. It has therefore been promoted to  
352 pharmacists and cattle-owners by conservationists across South Asia. Such advocacy has been  
353 particularly successful in Nepal. This has been aided by national and local government bodies  
354 promoting meloxicam after the ban on veterinary diclofenac in 2006, and later instigating a



355 diclofenac-for-meloxicam exchange programme in 2010. Similar advocacy in Bangladesh, including  
356 distributing meloxicam to pharmacists and veterinarians free of charge, has helped this drug to  
357 maintain its market share, although it lags well behind ketoprofen.

358

359 Meloxicam is an effective painkiller. In a review of experimental and clinical studies, 79% of 117  
360 studies reported positive effects of the drug on domesticated animals (SAVE 2016). However, many  
361 formulations of meloxicam are disliked by users because they cause the animal pain when injected,  
362 which is associated with the high pH and high osmolarity of meloxicam formulations produced in  
363 India (Cuthbert *et al.* 2014b), which are higher than that of the original formulation produced in  
364 Europe. Subsequently, a number of regional pharmaceutical companies have been able to replicate  
365 the original meloxicam formulation after the developer relaxed its patent (C. Bowden, unpublished  
366 information).

367

368 *The appearance of new NSAIDs*

369

370 Several other NSAIDs are widely available, some of which are known to be toxic to vultures, the most  
371 prevalent being nimesulide and ketoprofen. With the decline of the once-ubiquitous diclofenac,  
372 there are now gaps in the market that pharmaceutical companies are keen to fill with alternatives.  
373 For instance, in Nepal, one company promoted its nimesulide product by distributing it without  
374 charge (K. Bhusal, unpublished information).

375

376 In a nationwide study of dead vultures in India, post-mortem analysis revealed nimesulide residues  
377 in five (of 62) dead vultures, four of which had extensive visceral gout, a symptom of NSAID toxicity  
378 formerly only associated with high diclofenac residues (Cuthbert *et al.* 2016). Confirming that  
379 nimesulide is indeed toxic to *Gyps* vultures, two captive Cape Griffon Vultures *G. coprotheres* that

380 were unable to be released due to injury were dosed (by oral gavage) with nimesulide during safety  
381 testing, and died displaying symptoms of NSAID toxicity (Galligan *et al.* in prep.).

382  
383 Ketoprofen has been shown in safety tests on captive birds to be nephrotoxic to vultures (Naidoo *et*  
384 *al.* 2010). Although the drug has not yet been found in carcasses of wild vultures, lethal  
385 concentrations have been found in cattle carcasses in India (Taggart *et al.* 2009). Following advocacy  
386 by conservationists, the Government of Bangladesh banned veterinary use of ketoprofen in the two  
387 pVSZs in 2016, but this appears to have been only partially successful in reducing the drug's  
388 availability, despite an intensive awareness-raising campaign and promotion of meloxicam. One  
389 reason for its apparent resilience in the market may be the unfounded rumour that ketoprofen is  
390 safe to use on pregnant animals while meloxicam is not, which is not substantiated by published  
391 experimental and clinical studies, none of which even examined ketoprofen and pregnancy (SAVE  
392 2016). Conversations with pharmacy owners during the third survey revealed that they were almost  
393 all aware of the ban on ketoprofen and that some were selling stocks acquired before the ban  
394 (A.B.M.S. Alam, unpublished information).

395  
396 Other NSAIDs were available, usually at low prevalence, but including several known or suspected to  
397 be toxic to vultures, such as aceclofenac and flunixin. Aceclofenac is structurally very similar to  
398 diclofenac and is metabolised to the latter in various species of mammal, including cattle (Sharma  
399 2012; Galligan *et al.* 2016); therefore, aceclofenac is expected to have the same effect on vultures as  
400 diclofenac (Galligan *et al.* 2016). Although almost always sold in bolus form in our survey, injectable  
401 aceclofenac has recently been approved by the Indian government (C. Bowden, unpublished  
402 information). Several formulations are already available, so it could become a more popular  
403 veterinary drug in the future. Given the high levels of diclofenac that are formed in cattle tissues  
404 soon after injection of aceclofenac (Galligan *et al.* 2016), any future increase in sales of aceclofenac  
405 is expected to have devastating effects on the remaining populations of vultures.

406

407 Elevated flunixin residues, along with severe visceral gout, have been found in the carcasses of  
408 Eurasian Griffon Vultures *Gyps fulvus* in Spain (Zorrilla *et al.* 2014, R. Mateo, Pers. Comm.), the first  
409 reported instances of NSAID poisoning in wild vultures outside of South Asia. Flunixin was also  
410 responsible for the death of two captive Rüppell's Vultures *G. rueppellii* and one captive African  
411 White-backed Vulture *G. africanus* at a zoo in Rome, Italy (Eleni *et al.* 2019).

412

413 More encouraging was the increasing presence of tolfenamic acid, especially in Nepal and  
414 Bangladesh. Initial safety testing of this drug on *Gyps* vultures suggests that it may be non-toxic to  
415 vultures (Sharma *et al.* in prep). This would provide veterinarians and farmers with an additional  
416 vulture-safe drug, alongside meloxicam. One other drug, piroxicam, was also commonly available in  
417 Madhya Pradesh and Uttar Pradesh in the last surveys in 2017, but little is known about its toxicity  
418 to vultures.

419

420 *Conservation recommendations*

421

422 The biggest threat to vultures continues to be the wide availability of diclofenac, despite having been  
423 banned by governments across South Asia. There is a clear need for greater implementation of these  
424 bans, especially in India. Similarly, the ban on ketoprofen in pVSZs in Bangladesh needs to be  
425 extended throughout this (as proposed by the Government of Bangladesh in the *Bangladesh Vulture*  
426 *Conservation Plan (2016-2025)*) and other vulture range countries. There should also be bans on the  
427 veterinary use of aceclofenac and nimesulide, which have growing market shares.

428

429 Although awareness-raising has had some success, actions directed at pharmaceutical companies  
430 themselves may have a greater impact. This may particularly be the case in Bangladesh, where only a  
431 small number of companies manufacture ketoprofen. These companies also produce meloxicam and

17

432 tolfenamic acid, so their share of the drug market may not necessarily be adversely affected if they  
433 stop ketoprofen production.

434

435 A total of eleven different NSAIDs were recorded in this study, yet the results of safety testing have  
436 only been published for three of these drugs (diclofenac, meloxicam and ketoprofen). Such testing  
437 has been solely funded by conservation non-governmental agencies and academic sources, rather  
438 than governments or pharmaceutical companies within vulture-range countries. There is an urgent  
439 need to test these other drugs for toxicity to vultures experimentally, especially as other evidence of  
440 toxicity already exists for some of them, e.g. flunixin and nimesulide. Currently, meloxicam is the  
441 only NSAID that has been established as vulture-safe. Further safety testing of NSAIDs to identify  
442 other vulture-safe drugs, would give more choice to veterinarians and cattle-owners. Although  
443 meloxicam is known to be safe, in this survey up to half of products of this drug also contained  
444 paracetamol (India, 35%; Nepal, 43%; Bangladesh, 51%), for which there is no information regarding  
445 its safety to vultures, so the toxicity of this common painkiller also needs to be assessed. New  
446 veterinary NSAIDs should be tested for toxicity to vultures prior to their receiving government  
447 approval through the region. However, even more important than safety testing is that  
448 governments take action when the results from safety tests are available. Except for the ban on  
449 ketoprofen in the Bangladesh pVSZs, governments have not taken such action for other NSAIDs  
450 known to be toxic to vultures, such as aceclofenac or ketoprofen. Given that most veterinary NSAIDs  
451 used in South Asia are manufactured in India, this is an action which should be considered by the  
452 Indian government as part of their National Action Plan for Vulture Conservation (2019-2024) and  
453 their role in the Regional Declaration on the Conservation of South Asia's Critically Endangered  
454 Vulture Species (Anon 2012), which commits signatories to identifying and preventing the veterinary  
455 use of all vulture-toxic NSAIDs.

456

457 **Acknowledgements**

458 We wish to thank the Ministry of Environment, Forest and Climate Change, Government of India, the  
459 Ministry of Forests and Environment, Government of Nepal, the Forest Department and the Ministry  
460 of Environment, Forest and Climate Change, Government of Bangladesh and IUCN Bangladesh for  
461 their ongoing support for vulture conservation. The manuscript was greatly improved by the  
462 comments of Rubén Moreno-Opo and an anonymous reviewer. This work was funded by the RSPB.

463

#### 464 **References**

465 Anon (2012) *Regional Declaration on the Conservation of South Asia's Critically Endangered Vulture*  
466 *Species*. Governments of Bangladesh, India, Nepal and Pakistan, Delhi, May 2012.

467

468 Athanassoulis, N. and Wilson, J. (2009) When is deception in research ethical? *Clinical ethics* 4: 44-  
469 49.

470

471 Chaudhry, J. M. I., Ogada, D. L., Malik, R. N., Virani, M. Z. and Giovanni, M. D. (2012) First evidence  
472 that populations of the critically endangered Long-billed Vulture *Gyps indicus* in Pakistan have  
473 increased following the ban of the toxic veterinary drug diclofenac in South Asia. *Bird Cons. Int.*  
474 22: 389–397.

475

476 Cuthbert, R. J., Dave, R., Chakraborty, S. S., Kumar, S., Prakash, S., Ranade, S. P. and Prakash, V.

477 (2011) Assessing the ongoing threat from veterinary non-steroidal anti-inflammatory drugs to  
478 critically endangered *Gyps* vultures in India . *Oryx* 45: 420–426.

479

480 Cuthbert, R.J., Taggart, M.A., Prakash, V., Chakraborty, S.S., Deori, P., Kulkarni, M., Ranade, S., Saini. M.,

481 Sharma, A.K, Shringarpure, R. and Green, R.E. (2014a) Avian scavengers and the threat from

482 veterinary pharmaceuticals. *Phil. Trans. Roy. Soc. B* 20130574.

483

- 484 Cuthbert, R.J., Paudel, S., Chaudhary, A., Kaphle, K., Thapa, J., Subedi, T.R. and Taggart, M.A. (2014b)  
485 Aligning species conservation with animal welfare: formulation of vulture-safe meloxicam  
486 manufactured in South Asia and the reaction of goats to its administration. *RSPB Research Report*  
487 *No. 52*. Royal Society for the Protection of Birds, Sandy, Bedfordshire, UK.  
488
- 489 Cuthbert, R. J., Taggart, M. A., Mohini, S., Sharma, A., Das, A., Kulkarni, M. D., Deori, P., Ranade, S.,  
490 Shringarpure, R. N., Galligan, T. H. and Green, R. E. (2016) Continuing mortality of vultures in  
491 India associated with illegal veterinary use of diclofenac and a potential threat from nimesulide.  
492 *Oryx* 50: 104–112.  
493
- 494 Eleni, C., Neri, B., Giannetti, L., Grifoni, G., Meoli, R., Stravino, F., Friedrich, K.G., Scholl, F., Di Cerbo,  
495 P. and Battisti, A. (2019) Death of captive-bred vultures caused by flunixin poisoning in Italy.  
496 *Environ. Toxicol. Pharm.* 68: 91-93.  
497
- 498 Flourie, T., Cromarty, D., Duncan, N., Wolter, K. and Naidoo, V. (2015) The safety and  
499 pharmacokinetics of carprofen, flunixin and phenylbutazone in the Cape Vulture (*Gyps*  
500 *coprotheres*) following oral exposure. *PLoS One* 10: e0141419.  
501
- 502 Galligan, T. H., Taggart, M. A., Cuthbert, R. J., Svobodova, D., Chipangura, J., Alderson, D., Prakash, V.  
503 M. and Naidoo, V. (2016) Metabolism of aceclofenac in cattle to vulture-killing diclofenac. *Cons.*  
504 *Biol.* 30: 1122–1127.  
505
- 506 Galligan, T.H., Bhusal, K.P., Paudel, K., Chapagain, D., Joshi, A.B., Chaudhary, I.P., Chaudhary, A.,  
507 Baral, H.M., Cuthbert, R.J. and Green, R.E. (2019) Partial recovery of Critically Endangered *Gyps*  
508 vulture populations in Nepal. *Bird Cons. Int.* doi:10.1017/S0959270919000169.  
509

- 510 Green, R. E., Newton, I., Shultz, S., Cunningham, A. A., Gilbert, G., Pain, D. J. and Prakash, V. (2004)  
511 Diclofenac poisoning as a cause of vulture population declines across the Indian subcontinent. *J.*  
512 *App. Ecol.* 41: 793–800.  
513
- 514 Green, R. E., Taggart, M. A., Senacha, K. R., Raghavan, B., Pain, D. J., Jhala, Y. and Cuthbert, R. (2007)  
515 Rate of decline of the Oriental White-Backed Vulture population in India estimated from a survey  
516 of diclofenac residues in carcasses of ungulates. *PLoS ONE* 2: e686.  
517
- 518 Naidoo, V., Wolter, K., Cromarty, D., Diekman, M., Duncan, N., Meharg, A. A., Taggart, M. A., Venter,  
519 L. and Cuthbert, R. (2010) Toxicity of non-steroidal anti-inflammatory drugs to *Gyps* vultures: a  
520 new threat from ketoprofen. *Biol. Lett.* 6: 339–341.  
521
- 522 Naidoo, V., Taggart, M. A., Duncan, N., Wolter, K., Chipangura, J., Green, R. E. and Galligan, T. H.  
523 (2018) The use of toxicokinetics and exposure studies to show that carprofen in cattle tissue  
524 could lead to secondary toxicity and death in wild vultures. *Chemosphere* 190: 80-89.  
525
- 526 Oaks, J. L., Gilbert, M., Virani, M. Z., Watson, R. T., Meteyer, C. U., Rideout, B. A., Shivaprasad, H. L.,  
527 Ahmed, S., Chaudhry, M. J. I., Arshad, M., Mahmood, S., Ali, A. and Khan, A. A. (2004) Diclofenac  
528 residues as the cause of population decline of vultures in Pakistan. *Nature* 427: 630–633.  
529
- 530 Prakash, V., Green, R. E., Pain, D. J., Ranade, S. P., Saravanan, S., Prakash, N., Venkitachalam, R.,  
531 Cuthbert, R., Rahmani, A. R. and Cunningham, A. A. (2007) Recent changes in populations of  
532 resident *Gyps* vultures in India. *J. Bomb. Nat. Hist. Soc.* 104:129–135.  
533

- 534 Prakash, V., Galligan, T. H., Chakraborty, S. S., Dave, R., Kulkarni, M. D., Prakash, N., Shringarpure, R.  
535 N., Ranade, S. P. and Green, R. E. (2017) Recent changes in populations of Critically Endangered  
536 *Gyps* vultures in India. *Bird Cons. Int.* 29: 55-70.
- 537
- 538 SAVE 2016 NSAID Alerts. <https://save-vultures.org/alerts/> Downloaded on 20 December 2017.
- 539
- 540 Shultz, S., Baral, H. S., Charman, S., Cunningham, A. A., Das, D., Ghalsasi, G. R., Goudar, M. S., Green,  
541 R. E., Jones, A., Nighot, P., Pain, D. J. and Prakash, V. (2004) Diclofenac poisoning is widespread in  
542 declining vulture populations across the Indian subcontinent. *Proc. Roy. Soc. Lond. B*  
543 *(Supplement)* 271: S458–S460.
- 544
- 545 Spicker, P. (2011) Ethical covert research. *Sociology*, 45: 118-133.
- 546
- 547 Swan, G. E., Cuthbert, R., Quevedo, M., Green, R. E., Pain, D. J., Bartels, P., Cunningham, A. A.,  
548 Duncan, N., Meharg, A. A., Oaks, L., Jones, J. M., Shultz, S., Taggart, M. A., Verdoorn, G. and  
549 Wolter, K. (2006a) Toxicity of diclofenac to *Gyps* vultures. *Biol. Lett.* 2: 279–282.
- 550
- 551 Swan, G., Naidoo, V., Cuthbert, R., Green, R. E., Pain, D. J., Swarup, D., Prakash, V., Taggart, M.,  
552 Bekker, L., Das, D., Diekmann, J., Diekmann, M., Killian, E., Meharg, A., Patra, R. C., Saini, M. and  
553 Wolter, K. (2006b) Removing the threat of diclofenac to Critically Endangered Asian Vultures.  
554 *PLoS Biol.* 4: 396–402.
- 555
- 556 Swarup, D., Patra, R.C., Prakash, V., Cuthbert, R., Das, D., Avari, D.J., Pain, D.J., Green, R.E., Sharma,  
557 A.K., Saini, M., Das, D. and Taggart, M. (2007) Safety of meloxicam to critically endangered *Gyps*  
558 vultures and other scavenging birds in India. *Anim. Conserv.* 10: 192-198.
- 559



- 560 Taggart, M. A., Senacha, K. R., Green, R. E., Jhala, Y., Raghavan, B., Rahmani, A., Cuthbert, R., Pain, D.  
561 J. and Meharg, A. A. (2007) Diclofenac residues in carcasses of domestic ungulates available to  
562 vultures in India. *Environ. Int.* 33: 759–765.
- 563
- 564 Taggart M.A., Senacha K.R., Green R.E., Cuthbert R., Jhala Y.V., Meharg A.A., Mateo R. and Pain D.J.  
565 (2009) Analysis of Nine NSAIDs in Ungulate Tissues Available to Critically Endangered Vultures in  
566 India. *Environ. Sci. Technol.* 43, 4561-4566.
- 567
- 568 Zorrilla, I., Martinez, R., Taggart, M. A. and Richards, N. (2014) Suspected flunixin poisoning of a wild  
569 Eurasian griffon vulture from Spain. *Cons. Biol.* 29: 587-592.
- 570
- 571
- 572

**Table 1.** The percentage of pharmacies that offered for sale the four most common NSAIDs for use in cattle, during covert (undercover) surveys in various regions of India in 2012-2017. N = the number of pharmacies that offered an NSAID.

Region	NSAID	Year					Region	NSAID	Year						
		2012	2013	2014	2015	2016			2017	2012***	2013***	2014	2015	2016	2017
	<b>N</b>	<b>40</b>	<b>38</b>	<b>41</b>	<b>34</b>	<b>17</b>		<b>N</b>	<b>35</b>	<b>34</b>					
Assam	Diclofenac	30.0	5.3	9.8	14.7	0.0	Jharkhand	Diclofenac	54.3	14.7					
	Meloxicam	57.5	92.1	75.6	70.6	76.5		Meloxicam	34.3	61.8					
	Nimesulide	5.0	2.6	9.8	2.9	23.5		Nimesulide	2.9	0.0					
	Piroxicam	0.0	0.0	0.0	0.0	0.0		Piroxicam	0.0	0.0					
	Other**	7.5	0.0	4.8	11.8	0.0		Other	8.6	23.5					
	<b>N</b>	<b>42</b>	<b>20</b>	<b>26</b>		<b>13</b>		<b>N</b>			<b>63</b>	<b>77</b>	<b>16</b>	<b>127</b>	
Central Gujarat	Diclofenac	31.0	15.0	15.4		46.2	Madhya Pradesh	Diclofenac			58.7	39.0	50.0	25.2	
	Meloxicam	45.2	60.0	57.7		15.4		Meloxicam			7.9	23.4	25.0	28.3	
	Nimesulide	11.9	15.0	15.4		7.7		Nimesulide			6.3	6.5	6.3	13.4	
	Piroxicam	2.4	0.0	0.0		0.0		Piroxicam			20.6	29.9	12.5	29.9	
	Other	9.5	10.0	11.5		30.8		Other			6.3	1.3	6.3	3.1	
	<b>N</b>	<b>34</b>	<b>43</b>			<b>16</b>		<b>N</b>	<b>56</b>						
Southern Gujarat	Diclofenac	11.8	7.0			37.5	Uttarakhand	Diclofenac	51.8						
	Meloxicam	41.2	39.5			37.5		Meloxicam	16.1						
	Nimesulide	32.4	37.2			18.8		Nimesulide	5.4						
	Piroxicam	0.0	0.0			0.0		Piroxicam	17.9						
	Other	14.7	16.3			6.3		Other	8.9						
	<b>N</b>				<b>33</b>	<b>83</b>		<b>N</b>	<b>50</b>	<b>11</b>	<b>89</b>	<b>32</b>	<b>59</b>		
Haryana pVSZ*	Diclofenac				3.0	9.6	Uttar Pradesh	Diclofenac	72.0	18.2	31.5	21.9	20.3		
	Meloxicam				69.7	43.4		Meloxicam	6.0	18.2	12.4	3.1	27.1		
	Nimesulide				18.2	37.3		Nimesulide	6.0	9.1	29.2	3.1	23.7		
	Piroxicam				0.0	2.4		Piroxicam	14.0	54.5	20.2	71.9	25.4		
	Other				9.1	7.2		Other	2.0		6.7		3.4		

\* Included neighbouring areas of Himachal Pradesh and Punjab

\*\* 'Other' NSAIDs include: aceclofenac, metamizole (Analgin), ketoprofen, mefenamic acid, phenylbutazone and tolfenamic acid

\*\*\* A different method was used in surveys in 2012 and 2013 in Jharkhand, Uttarakhand and Uttar Pradesh (see Methods)

**Table 2.** Trends in the proportion of four NSAIDs offered for sale for use in cattle during covert (undercover) surveys of pharmacies in five regions of India between 2012 and 2017.

Region	(a) Diclofenac				(b) Meloxicam			
	<i>b</i>	SE	<i>t</i>	<i>P</i>	<i>b</i>	SE	<i>t</i>	<i>P</i>
Assam	<b>-0.471</b>	<b>0.20</b>	<b>2.39</b>	<b>0.018</b>	0.112	0.14	0.82	0.41
Central Gujarat	0.109	0.14	0.81	0.42	-0.209	0.13	1.59	0.11
Southern Gujarat	<b>0.374</b>	<b>0.15</b>	<b>2.55</b>	<b>0.012</b>	-0.029	0.12	0.24	0.81
Madhya Pradesh	<b>-0.426</b>	<b>0.10</b>	<b>4.14</b>	<b>&lt; 0.0001</b>	<b>0.348</b>	<b>0.12</b>	<b>2.83</b>	<b>0.005</b>
Uttar Pradesh	-0.306	0.20	1.55	0.12	<b>0.509</b>	<b>0.23</b>	<b>2.19</b>	<b>0.03</b>

Region	(c) Nimesulide				(d) Piroxicam			
	<i>b</i>	SE	<i>t</i>	<i>P</i>	<i>b</i>	SE	<i>t</i>	<i>P</i>
Assam	0.406	0.24	1.70	0.09				
Central Gujarat	-0.058	0.19	0.30	0.76				
Southern Gujarat	-0.155	0.14	1.10	0.28				
Madhya Pradesh	0.318	0.18	1.80	0.07	0.089	0.08	1.05	0.29
Uttar Pradesh	-0.210	0.20	1.03	0.30	0.205	0.18	1.14	0.26

**Table 3.** The percentage of pharmacies that offered for sale six NSAIDs for use in cattle, during covert (undercover) surveys in various regions of Nepal, 2012-2017. N = the number of pharmacies that offered an NSAID.

Region	NSAID	Year					
		2012	2013	2014	2015	2016	2017
	<b>N</b>					<b>38</b>	<b>68</b>
Eastern Terai	Diclofenac					2.6	1.2
	Meloxicam					79.0	89.9
	Nimesulide					5.3	1.2
	Piroxicam					2.6	0.0
	Ketoprofen					0.0	1.2
	Tolfenamic acid					10.5	6.5
	<b>N</b>	<b>36</b>	<b>65</b>	<b>71</b>			
Western Pahad	Diclofenac	0.0	0.0	0.0			
	Meloxicam	100	100	95.8			
	Nimesulide	0.0	0.0	2.8			
	Piroxicam	0.0	0.0	0.0			
	Ketoprofen	0.0	0.0	1.4			
	Tolfenamic acid	0.0	0.0	0.0			
	<b>N</b>	<b>21</b>	<b>72</b>	<b>56</b>	<b>15</b>	<b>51</b>	
Western Terai	Diclofenac	9.5	4.2	0.0	0.0	0.0	
	Meloxicam	90.5	95.8	98.2	100	84.3	
	Nimesulide	0.0	0.0	1.8	0.0	13.7	
	Piroxicam	0.0	0.0	0.0	0.0	0.0	
	Ketoprofen	0.0	0.0	0.0	0.0	0.0	
	Tolfenamic acid	0.0	0.0	0.0	0.0	2.0	

**Table 4.** Trends in the proportion of diclofenac and meloxicam offered for sale for use in cattle during covert (undercover) surveys of 'Animal' pharmacies in three regions of Nepal, 2012-2017. Models for the Western Pahad region did not converge. Superscript '2' denotes quadratic effect.

Region	Diclofenac				Meloxicam			
	<i>b</i>	SE	<i>t</i>	<i>P</i>	<i>b</i>	SE	<i>t</i>	<i>P</i>
Eastern Terai	-0.594	1.43	0.42	0.68	0.843	0.56	1.50	0.14
Western Terai	<b>-1.490</b>	<b>0.68</b>	<b>2.20</b>	<b>0.028</b>	<b>0.002</b>	<b>0.08</b>	<b>2.44</b>	<b>0.02</b>
					<b>-0.488</b>	<b>0.2</b>	<b>2.44</b>	<b>0.02</b>

**Table 5.** The percentage (of all NSAIDs stocked) of seven NSAIDs available for use on cattle, during covert (undercover) surveys of pharmacies in three regions of Bangladesh, 2014-2018. N = the total number of NSAIDs stocked by pharmacies. The first survey covered the whole of the country.

BANGLADESH		Year		
Region	NSAID	2014	2015/16	2018
Whole country	<b>N</b>	<b>340</b>		
	Diclofenac	6.5		
	Meloxicam	24.7		
	Nimesulide	0.0		
	Ketoprofen	67.1		
	Tolfenamic acid	0.3		
	Flunixin	0.3		
	Phenylbutazone	1.2		
Sylhet pVSZ	<b>N</b>		<b>197</b>	<b>197</b>
	Diclofenac		0.0	0.0
	Meloxicam		29.9	29.9
	Nimesulide		0.0	0.0
	Ketoprofen		67.0	67.0
	Tolfenamic acid		3.0	3.0
	Flunixin		0.0	0.0
	Phenylbutazone		0.0	0.0
Khulna pVSZ	<b>N</b>		<b>177</b>	<b>184</b>
	Diclofenac		1.7	0.0
	Meloxicam		21.5	37.0
	Nimesulide		0.0	0.0
	Ketoprofen		72.3	56.0
	Tolfenamic acid		3.4	5.4
	Flunixin		0.6	1.6
	Phenylbutazone		0.6	0

**Figure legends**

**Figure 1.** Percentage of pharmacies that offered for sale for use in cattle (a) diclofenac, (b) meloxicam and (c) nimesulide during covert (undercover) surveys of pharmacies in five regions of India from 2012 to 2017. Regression lines from predicted values fitted from logistic regression model included to illustrate trends in sales of NSAIDs in the five regions. Note varying scale of y-axis.

**Figure 2.** Percentage of pharmacies that offered for sale for use in cattle (a) meloxicam, (b) diclofenac and (c) nimesulide during covert (undercover) surveys of pharmacies in three regions of Nepal from 2012 to 2017. Regression line from predicted values fitted from logistic regression model for the Western Terai region included to illustrate trends in sales of NSAIDs. No regression lines included for Eastern Terai, as only two surveys conducted. Models of trends in Western Pahad region did not converge. Note varying scale of y-axis.

**Figure 3.** Percentage of all NSAIDs stocked by pharmacies for use in cattle that were (a) ketoprofen, (b) meloxicam and (c) diclofenac during covert (undercover) surveys of pharmacies in Bangladesh from 2014 to 2018. The first survey covered the whole country, whereas later surveys were conducted in two provisional Vulture Safe Zones. Regression lines not included as regions only surveyed in 1-2 years. Note varying scale of y-axis.

Review Only




Figure 1a






Figure 1b




Figure 1c




Figure 2a




Figure 2b




Figure 2c




Figure 3a.

View Only




Figure 3b.

ew Only




Figure 3c.